Robert Mittendorff, MD

Dr. Mittendorff is a General Partner and Head of Healthcare who leads investments at B Capital in venture and growth opportunities in the sector. Previously, he was at Norwest Venture Partners for nearly a decade as a Partner and Co-Head of Healthcare. He has been involved in investments and associated exits with public equity value or acquisition value that exceeds a total of $10B. He is a board-certified emergency physician and former public company operating executive.

He has served on the boards of Impel Neuropharma, Avalyn Pharma, Qventus, and VisitPay, TigerConnect, Neocis, and was a board observer at Talkspace, Omada, and Route92. He was a board member at Silk Road Medical (SILK), iCardiac (acq. by eResearch), and Telcare (acq. by BioTelemetry). Prior to his career in venture capital, Dr. Mittendorff was an executive officer and the Vice President of Marketing and Business Development at Hansen Medical Inc. (Nasdaq: HNSN), acquired by Auris/JNJ.  He earned a Harvard M.D., trained at Stanford in Emergency Medicine, and received his M.B.A. from Harvard Business School and his B.S. in biomedical engineering from Johns Hopkins (high hon).

Elizabeth Williams

Ms. Williams has nearly 20 years of experience in biotech, working with publicly listed entities in both Canada and the United States. Ms. Williams is currently the CFO of Satellos Biosciences (TSX: MSCL) where she is responsible for all financial, legal, and investor relations functions of the Company. Prior to Satellos, Ms. Williams was the CFO of Medicenna Therapeutics (Nasdaq: MDNA) where she led the graduation of Medicenna from the TSX to Nasdaq and raised over $100M in capital during her tenure. Ms. Williams held senior roles at Aptose Biosciences Inc. (Nasdaq: APTO) and Ernst & Young LLP. Ms. Williams is a Chartered Professional Accountant (CPA) and Chartered Accountant (CA).

Connor McDermott

Connor McDermott is a Vice President at Northpond Ventures where he evaluates and supports biotechnology companies. Connor joined Northpond in 2019 as a member of the investment team and has conducted diligence on 16 closed investments in biotherapeutics companies. In addition to Triumvira, Connor is a Board Director for Transition Bio and is a Board Observer for Aro Biotherapeutics, Faro Health, Garuda Therapeutics, Opna Bio, Totus Medicines, and Walking Fish Therapeutics. Previously, Connor worked in Investment Banking at Leerink Partners, a life science-focused investment bank, where he supported biotechnology companies on business development, IPOs, and M&A transactions. Connor earned a B.A. in Biology and a B.A. in Economics from Brown University.

Julie Yang

Julie (Jr-Shiuan) Yang has 15+ years of life sciences experience across investing, biotech, and academia. She joined Leaps by Bayer as Senior Director, Venture Investments in May 2023. Prior to this, she was Vice President at Bain Capital Life Sciences, where she focused on evaluating early-to-mid stage companies developing therapeutics across modalities and indications. She was a drug developer for the cardiovascular and rare disease programs at Dicerna Pharmaceuticals, Inc. She earned her PhD in molecular biology and biochemistry at Weill Cornell Graduate School of Medical Sciences, and her MBA from INSEAD.

Robert Williamson

Robert F. Williamson, III has been active in building biotechnology companies and shareholder value for over two decades. He currently is the President and COO of Triumvira Immunologics. Previously, he was the CBO of OncoMyx, an oncolytic virus company, and CEO of BioTheryX, a protein degradation therapeutics company, raising a $100M crossover round and preparing the company for an IPO. Prior to BioTheryX, Mr. Williamson served as CEO of both PharmAkea and ATXCo, oncology and fibrosis companies financed through a partnership with Celgene, until PharmAkea’s acquisition by Galecto and ATXCo’s acquisition by Blade Therapeutics. Prior, Mr. Williamson was CEO of Arriva Pharmaceuticals, President and COO of Eos Biotechnology, which he sold to Protein Design Labs, and COO of DoubleTwist, Inc. through its acquisition by Merck and Hitachi.

Mr. Williamson also serves as a director and adviser for foundations, private, and public companies. Notably, Mr. Williamson served as an early Director of Pharmasset, Inc., where he helped finance, grow, and advance the company into the public markets and through its acquisition by Gilead in 2011 for $11 billion. Earlier, Mr. Williamson was a partner with The Boston Consulting Group and a research assistant for the Federal Reserve Board. He received a BA in economics from Pomona College and an MBA from Stanford.